Capricor Therapeutics Inc.

4.41-0.1000-2.22%Vol 369.92K1Y Perf -19.61%
Jun 27th, 2022 16:00 DELAYED
BID4.20 ASK4.74
Open4.60 Previous Close4.51
Pre-Market- After-Market4.56
 - -  0.15 3.40%
Target Price
15.00 
Analyst Rating
Strong Buy 1.00
Potential %
240.14 
Finscreener Ranking
★★★ —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★+     42.44
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★     44.38
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
56.23 
Earnings Rating
Neutral
Market Cap107.27M 
Earnings Date
11th Aug 2022
Alpha0.03 Standard Deviation0.72
Beta5.39 

Today's Price Range

4.314.75

52W Range

2.565.85

5 Year PE Ratio Range

-3.0028.60

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
0.23%
1 Month
21.15%
3 Months
14.55%
6 Months
48.48%
1 Year
-19.61%
3 Years
32.83%
5 Years
-44.18%
10 Years
-91.18%

TickerPriceChg.Chg.%
CAPR4.41-0.1000-2.22
AAPL141.660.00000.00
GOOG2 332.45-38.3100-1.62
MSFT264.89-2.8100-1.05
XOM89.032.13002.45
WFC40.24-0.5200-1.28
JNJ182.12-0.1700-0.09
FB196.640.99000.51
GE66.71-0.2900-0.43
JPM116.38-0.9400-0.80
Financial StrengthValueIndustryS&P 500US Markets
4.10
4.20
0.09
0.11
-
Leverage Ratio 1.50
ProfitabilityValueIndustryS&P 500US Markets
-
-11 568.30
-11 427.20
-2 831.20
-
RevenueValueIndustryS&P 500US Markets
204.08K
0.01
-45.43
-43.70
Earnings HistoryEstimateReportedSurprise %
Q01 2022--0.32-
Q04 2021-0.19-0.26-36.84
Q03 2021-0.22-0.1722.73
Q02 2021-0.23-0.218.70
Q01 2021--0.23-
Q03 2020--0.20-
Q02 2020-0.37-0.2337.84
Q01 2020-0.36-0.3016.67
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.2568.75Positive
9/2022 QR-0.26--
12/2022 FY-1.10--
12/2023 FY-1.22--
Next Report Date11th Aug 2022
Estimated EPS Next Report-0.25
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume369.92K
Shares Outstanding24.32K
Shares Float23.64M
Trades Count1.44K
Dollar Volume1.69M
Avg. Volume126.35K
Avg. Weekly Volume119.67K
Avg. Monthly Volume102.92K
Avg. Quarterly Volume156.46K

Capricor Therapeutics Inc. (NASDAQ: CAPR) stock closed at 4.41 per share at the end of the most recent trading day (a -2.22% change compared to the prior day closing price) with a volume of 369.92K shares and market capitalization of 107.27M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 16 people. Capricor Therapeutics Inc. CEO is Linda Marban.

The one-year performance of Capricor Therapeutics Inc. stock is -19.61%, while year-to-date (YTD) performance is 50.51%. CAPR stock has a five-year performance of -44.18%. Its 52-week range is between 2.56 and 5.85, which gives CAPR stock a 52-week price range ratio of 56.23%

Capricor Therapeutics Inc. currently has a PE ratio of -4.70, a price-to-book (PB) ratio of 4.45, a price-to-sale (PS) ratio of 525.62, a price to cashflow ratio of 10.10, a PEG ratio of 2.32, a ROA of -42.79%, a ROC of -70.74% and a ROE of -76.92%. The company’s profit margin is -%, its EBITDA margin is -11 427.20%, and its revenue ttm is $204.08 Thousand , which makes it $0.01 revenue per share.

Of the last four earnings reports from Capricor Therapeutics Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.25 for the next earnings report. Capricor Therapeutics Inc.’s next earnings report date is 11th Aug 2022.

The consensus rating of Wall Street analysts for Capricor Therapeutics Inc. is Strong Buy (1), with a target price of $15, which is +240.14% compared to the current price. The earnings rating for Capricor Therapeutics Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Capricor Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Capricor Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 20.33, ATR14 : 0.25, CCI20 : 139.93, Chaikin Money Flow : 0.02, MACD : 0.27, Money Flow Index : 86.27, ROC : 26.33, RSI : 69.94, STOCH (14,3) : 91.60, STOCH RSI : 1.00, UO : 53.07, Williams %R : -8.40), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Capricor Therapeutics Inc. in the last 12-months were: David B. Musket (Option Excercise at a value of $43 913), Earl M. Collier (Option Excercise at a value of $21 482), Frank Litvack (Option Excercise at a value of $214 815), George W. Dunbar (Option Excercise at a value of $21 482), Louis V. Manzo (Option Excercise at a value of $38 787)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a United State-based clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy, and other medical conditions. The company's development stage drug candidates for cardiovascular diseases include CAP-1002 that is in Phase II clinical trials; and CAP-2003, which is in pre-clinical development for the treatment of certain cardiac and inflammatory conditions.

CEO: Linda Marban

Telephone: +1 310 358-3200

Address: 8840 Wilshire Boulevard, Beverly HIlls 90211, CA, US

Number of employees: 16

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

73%27%

Bearish Bullish

59%41%

News

Stocktwits